Healthcare
·
Biotechnology
VRTX added 7.5% in the latest week and closed just 0.2% below its 52-week high, but the Sharemaestro read remains balanced because the weekly Trend Signal is still inactive and participation has returned to baseline.
Healthcare
·
Biotechnology
The ADR gained 5.9% in the latest week and sits just 1.5% below its 52-week high, but the move lacks volume confirmation and carries a stretched premium to Sharemaestro Fair Value.
Healthcare
·
Diagnostics & Research
Illumina closed just 0.4% below its 52-week high after another strong week, but average volume and selective industry participation keep the confirmation bar in view.
Healthcare
·
Drug Manufacturers - General
ABBV closed within 0.2% of its 52-week high after a 14.9% four-week run, but the latest advance came on 0.9x volume and leaves valuation distance stretched.
Healthcare
·
Drug Manufacturers - Specialty & Generic
The ADR remains in an active weekly Trend Signal and above its Trend Line, yet participation fell well below normal as the stock worked back toward the top of its 52-week range.
Healthcare
·
Medical Instruments & Supplies
West Pharmaceutical Services closed just 0.5% below its 52-week high after a strong three-month advance, but the latest week’s participation was below average.
Healthcare
·
Biotechnology
Ascendis Pharma closed at $274.50, only 0.1% below its 52-week high, after a four-week advance of 30.4%. The Trend backdrop remains active, but lighter volume and a wide Fair Value premium keep the weekly read balanced rather than emphatic.
Healthcare
·
Healthcare Plans
Centene closed just 2.1% below its 52-week high, with the managed-care group providing strong confirmation even as the latest advance came on only 0.7x recent volume.
Healthcare
·
Medical Distribution
CAH finished 1.0% below its 52-week high after a 7.3% week on 13.1M shares, with trend and relative-strength evidence positive but activity pressure still only modest.
Healthcare
·
Diagnostics & Research
Revvity closed at $113.0 after a volume-backed weekly advance, leaving the diagnostics stock just 4.4% below its 52-week high while Sharemaestro’s broader signal read remains balanced.
Healthcare
·
Drug Manufacturers - General
LLY finished at $1,208 after a strong week on above-average participation, but the stock now sits 51.1% above Sharemaestro Fair Value as Healthcare breadth remains selective.
Healthcare
·
Drug Manufacturers - Specialty & Generic
Viatris rose 6.2% for the week and remains high in its 52-week range, but average participation and an undecided expectancy read keep the setup balanced.
Healthcare
·
Health Information Services
BTSG added 4.1% for the week and finished only 2.5% below its 52-week high, with participation running at 1.5x the 13-week average. The trend remains strong, but valuation distance and recent reversal markers raise the bar for further clean
Healthcare
·
Drug Manufacturers - Specialty & Generic
The NYSE-listed ADR rose 15.7% on 19.8M shares, moving within 1.9% of its 52-week high, although Sharemaestro’s regime evidence remains only balanced.
Healthcare
·
Drug Manufacturers - General
Novartis outpaced its drugmaker group for the week on heavy volume, yet the broader confirmation picture is mixed as Market Dynamics remains below zero.